Healthcare Distribution Alliance – Patients Move Us.

+ About
- Role of Distributors
- Membership
- HDA History
- Member Directory
- Staff Directory
- Industry Recognition
- Executive Committee
- Mission and Values
- Board of Directors
- Join HDA
- Councils and Committees
- Careers
- About
  
  Information regarding HDA's history, leadership, mission, values and staff.
+ Issues
- COVID-19 Response
- Healthcare Affordability
- Pharmaceutical Traceability
- Distributor Licensure
- Importation of Prescription Medicines
- Drug Product Availability
- Prescription Drug Abuse and Diversion
- Emergency Preparedness
- Taxes
- Grassroots Advocacy
- Issues
  
  HDA reviews key priority issues and advocates on behalf of its pharmaceutical distributor members for standards, public policies and business processes that ensure a safe and efficient supply chain.
+ Events
- Distribution Management Conference and Expo
- PCSC Educational Seminar
- Business and Leadership Conference
- Webinars
- Annual Board and Membership Meeting
- Speaker Resource Center
- Traceability Seminar
- Events
  
  HDA regularly brings members and key healthcare supply chain stakeholders together to share industry information, learn about best practices, and be introduced to new products and services.
+ News
- Press Releases
- Blog
- Testimony
- HDA in the News
  
  Press releases, public testimony executive statements and information on HDA's efforts on behalf of pharmaceutical distributors and the supply chain.
+ Resources
- Publications
- COVID-19 Response
- Health Delivered
- Professional Development
- Webinars
- PCSC
- Allied Against Opioid Abuse
- Annual Report
- Resources
  
  HDA and the HDA Research Foundation produce a variety of resources to enhance the value of the supply chain and increase industry knowledge.

Share Print

Home | News

News

HDA Statement on FDA Authorization of Johnson & Johnson COVID-19 Vaccine

February 27, 2021

HDA President and CEO Chester “Chip” Davis, Jr., released a statement regarding the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization (EUA) for the Johnson & Johnson...

AAOA Marks Three Years of Collaborative Efforts to Increase Rx Opioid Safety Awareness

February 25, 2021

February marks Allied Against Opioid Abuse’s (AAOA) third year of bringing together healthcare stakeholders to increase awareness about prescription opioid safety.

HDA Statement on COVID-19 Vaccine Distribution and Role of Distribution Industry

January 22, 2021

HDA President and CEO Chester “Chip” Davis, Jr., released the following statement in response to recent commentary related to the COVID-19 vaccination effort.

HDA Statement on Biden Administration COVID-19 Relief and Vaccine Distribution Plan

January 16, 2021

HDA President and CEO Chester “Chip” Davis, Jr., released a statement following President-elect Biden’s introduction of a COVID-19 vaccination plan.

View Archives

Results: 38 Articles found.

Previous | Next

HDA Statement on Biden-Harris Inauguration
January 20, 2021

Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., issued the following statement.
HDA Statement on Biden Administration COVID-19 Relief and Vaccine Distribution Plan
January 16, 2021

HDA President and CEO Chester “Chip” Davis, Jr., released a statement following President-elect Biden’s introduction of a COVID-19 vaccination plan.
HDA Research Foundation Names Supply Chain Scholars
January 13, 2021

The HDA Research Foundation has conferred four graduate-level scholarships to pharmaceutical supply chain leaders.
HDA Statement on COVID-19 Emergency Relief Package
December 22, 2020

HDA President and CEO Chester “Chip” Davis, Jr., released a statement commenting on passage of the COVID-19 emergency relief package by the U.S. House of Representatives and the U.S. Senate.
HDA Statement on FDA Authorization of Moderna Vaccine
December 18, 2020

HDA President and CEO Chester “Chip” Davis, Jr., released a statement following the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization for the Moderna COVID-19 vaccine candidate.

Previous | Next

Media Contacts

John Parker
(703) 885-0216

Farah Simonett
(703) 885-0269

Privacy | Antitrust | Sitemap | Terms of Use | Contact